Speaker - Kevin Lustig

 Kevin  Lustig  Thumbnail


Kevin has spent most of the past 28 years either managing research groups or running his own experiments at the bench. He is co-founder and CEO of Assay Depot, which owns and operates a network of online research exchanges that have the potential to dramatically improve how research outsourcing is done. In 2001, Kevin co-founded Kalypsys, a fully integrated drug discovery company that raised over $170 million in venture funding and put five drug candidates into human clinical trials.

Prior to Kalypsys, he directed lead discovery at Tularik, a highly successful biopharmaceutical company purchased by Amgen for more than $2 billion. He carried out postdoctoral work in Cell Biology at Harvard Medical School after receiving a PhD degree from Marc Kirschner’s laboratory in the Department of Biochemistry & Biophysics at the University of California, San Francisco (UCSF).

Kevin has a M.S. degree in Biochemistry from the University of Missouri-Columbia and an A.B. degree, magna cum laude, in Molecular and Cell Biology from Cornell University’s College of Arts and Sciences. His research discoveries have been published in Science magazine and other leading scientific journals and he has been awarded eight technology patents.

1 Program

Leveraging Open Science for Rare Diseases

10.20.12 | 01:45:18 min | 0 comments